Keymed Biosciences’ Stapokibart Receives First Prescription in China for IL-4Rα Targeting Therapy

China-based biotech company Keymed Biosciences Inc. (HKG: 2162) has reached a significant milestone with its drug candidate stapokibart, as it receives its first prescription in the country. This marks a pivotal step for the IL-4Rα monoclonal antibody (mAb), which is the first drug developed by a Chinese biotech to target the human IL-4 receptor alpha subunit (IL-4Rα). Stapokibart is designed to selectively bind to IL-4Rα, thereby blocking the interaction with IL-4 and IL-13, which are key drivers of immune response in conditions such as moderate to severe atopic dermatitis (AD). The drug’s approval and initial prescription highlight the growing capabilities of China’s biopharmaceutical sector in bringing innovative therapies to market. -Fineline Info & Tech